Objectives: To screen novel small molecule compounds for inhibition of Mycoplasma bovis growth and to characterize their activity in terms of dose-dependency and ability to function in milk.
Introduction
Mycoplasma bovis, a pathogenic mycoplasma that affects cattle, is associated with numerous disease states. 1 Mastitis and pneumonia caused by M. bovis are complex multifactorial diseases that are some of the most difficult bacterial infections to treat and control. Due to the lack of a cell wall, antimicrobials targeting that region, such as b-lactams, are ineffective. 1 Additionally, increased resistance to frequently administered veterinary antimicrobials, such as spectinomycin, tetracycline and tilmicosin have been recorded. 1 It is necessary to consider alternatives in order to continue combating M. bovis infections.
One suggested method is through the use of novel natural compounds. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays, a colorimetric test based upon reduction of tetrazolium, have been successfully used on multiple mycoplasma species, allowing for quantitative evaluation of growth, inhibition or chemosensitivity. 2, 3 The objectives of this study were to: (i) screen novel small molecule compounds for inhibition of M. bovis growth; (ii) evaluate the potential of a dose-dependent response; and (iii) determine whether inhibition of M. bovis was possible in a milk environment using novel small molecule natural compounds.
Materials and methods
Mycoplasma cytotoxicity assays were performed using the Cell Counting Kit-8 (CCK-8) (Dojindo Technologies Inc., Rockville, MD, USA), which utilizes a water soluble tetrazolium salt. The TimTec (TimTec Inc., Newark, DE, USA) natural compound library of 480 compounds was screened. Mycoplasma bovis PG45 cultures (ATCC 25523) were grown to log phase growth ( 5×10 3 cells/mL) according to previously described procedures. 2 A final compound concentration of 10 mM was added to each inoculum broth well in a sterile 96-well round bottom plate. An enrofloxacin concentration of 0.000032 mg/L and a florfenicol concentration of 0.000512 mg/L (Sigma-Aldrich, St Louis, MO, USA) were selected as positive controls. Additionally, medium alone, medium with 10% DMSO, M. bovis culture alone and culture with 10% DMSO (Sigma-Aldrich) were run with every plate. Samples were incubated at 378C in 5% CO 2 for 4 h, when 10% (v/v) CCK-8 was added. The absorbance was read 20 h after addition of CCK-8 at 450 nm using a microplate reader (FlexStation3, Molecular Devices, Sunnyvale, CA, USA). The medium alone and medium with 10% DMSO showed no detectable difference in absorbance readings, with a range of 0.2 to 0.5.
Necessitated by a report that some compounds with a thiol group could interfere with MTT assays, 4 the impact of a small molecule natural compound's ability to interfere with the cytotoxicity assay was determined. Each of the compounds identified as able to inhibit the growth of M. bovis was tested in the presence of CCK-8 under the testing conditions without the presence of M. bovis culture.
Methanesulphonic
, eriodictyol (E) and (+)-a-tocopherol acid succinate (AAC) were tested with final compound concentrations of 20, 10 and 1 mM of each compound using the same protocol performed in the screening of the natural compound library.
The Z-factor statistic was calculated to provide evaluation and comparison of the quality of the high-throughput assay used in this study. The Z-factor was determined using the ratio previously described. 5 The power (Z-factor) of the high-throughput screening was calculated to be 0.6749, representing an 'excellent assay'. 5 MA, TCA, CC, AA, D, E and AAC were tested for their ability to inhibit growth of M. bovis in fresh, non-mastitic, mycoplasma-free quarter milk. Samples were obtained on the day of testing from the Pennsylvania State University dairy barns (somatic cell count 3/mL). Each sample of milk was spiked with M. bovis PG45 ( 2×10 4 cells/mL). Fresh quarter milk samples were treated with 1, 10, 20 and 40 mM of each of the selected compounds. Samples were incubated at 378C in 5% CO 2 . At 0, 3 and 24 h a 10 mL aliquot was spread on pleuropneumonia-like organism (PPLO) agar plates (U.C. Davis Veterinary Biological Media Services, Davis, CA, USA). Plates were incubated for 48 h at 378C in 5% CO 2 . Colony counts were performed using a light microscope. All samples were run in duplicate and the average colony count was recorded. Mycoplasma ssp. colonies were not detected on any of the negative control plates inoculated with fresh quarter milk. The relative growth of Table 1 . List of compounds shown to inhibit growth of Mycoplasma bovis using an in vitro tetrazolium salt reduction assay; compounds in bold type were selected for further study.
Name of compound
Chemical formula 
Results
It was determined that 32 of the 480 TimTec natural library compounds inhibited the growth of M. bovis at 10 mM (Table 1) . Following the first screening, each of the 32 compounds with inhibitory effects was tested without the presence of culture in order to determine the effect of each compound on absorbance readings in the presence of CCK-8, which showed absorbance values that were equivalent to that of medium with 10% DMSO. Based upon available current cellular cytotoxicity and pharmacology data, 7 of the 32 compounds were determined to be the best candidates for further testing ( Table 1 Soehnlen et al.
in fresh, non-mastitic, quarter milk samples at 1, 10, 20 and 40 mM compound concentrations. At time 0 treated samples had the same level of growth as the untreated control samples. At 3 h, the cultures treated with the natural compounds at 20 and 40 mM concentrations were similar to the growth inhibition of the cultures treated with florfenicol. The 24 h timepoint indicates that each concentration of AA and CC caused a similar level of inhibition, whereas AAC, E and TCA showed poor inhibition at a 1 mM concentration (Figure 1b) . Similar to the CCK-8 testing, there is a dose-dependent effect of each compound relating to inhibiting growth of M. bovis in a fresh quarter milk environment.
Discussion
The purpose of this study was to determine whether novel small molecule compounds have the potential to inhibit growth of M. bovis. A tetrazolium assay was selected to conduct these experiments due to previous success in Mycoplasma studies and suitability as a drug screening method. 2, 3 Previous reports demonstrated the potential of compounds with a thiol group to interfere with MTT assays. 4 Our results demonstrate that CCK-8, which is similar to MTT, is not impacted by the tested compounds. Based upon the acquired Z-factor value of 0.6749, the assay used for this study should be considered appropriate for identifying compounds capable of inhibiting the growth of M. bovis.
5
The results of the initial small molecule library screen indicated that 32 compounds had the ability to inhibit the growth of M. bovis (Table 1) . Many of the compounds would be inappropriate for use in cattle, while others have known cytotoxicity associated with them, therefore those compounds were not tested further. A dose-dependent response was noted for each of the seven compounds selected for further testing (Figure 1a and b). The compounds that were most effective at a concentration of 20 mM were MA and D in the dose -response testing. D at a concentration of 40 mM was also the most effective at both 3 h and 24 h in the fresh quarter milk experiments (Figure 1b) .
Although many natural compounds have been shown to have antibacterial or antiviral abilities, some natural compounds, such as CC, are also capable of acting as an anti-mucolytic and reducer of reactive oxygen and nitrogen species. 6 -8 Reports of increasing antimicrobial resistance in Europe and North America and the controversial use of certain antimicrobials, such as fluoroquinolones, has increased the need for alternative strategies. 1 The potential applications in organic and natural farming offer a new method for treating or preventing difficult to control diseases, such as M. bovis-associated mastitis. The use of an antimicrobial in a dairy cow results in a loss of their 'organic' status. 9 However, there is no currently approved therapeutic capable of treating mycoplasma mastitis for organic farmers. 9 Small molecule natural compounds may have the potential to serve the organic and natural farming communities in an effective and safe manner.
These overall results of the study suggest that the small molecule natural compounds MA, TCA, CC, AA, D, E and AAC are capable of inhibiting the growth of M. bovis in a dose-dependent manner. Based upon this information, these natural compounds have the potential to serve as therapeutics and prophylactics, lessening the dependency on current antimicrobials to which bacteria show increasing resistance, allowing for a promotion of animal and human health and well-being.
